Imic Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$555,436	4
2024	Research	$307,407	4
2023	Research	$94,685	2
2022	Research	$13,542	2
2021	Research	$28,185	2
2020	Research	$96,080	6
2019	Research	$3,876	1

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $856,947 8 payments
Celgene Corporation $128,406 9 payments
AstraZeneca Pharmaceuticals LP $113,859 4 payments

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $412,500 2 payments
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia $167,282 2 payments
Phase 2 PoC in Early AD Patients - A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimer s Disease (TargetT $143,224 1 payment
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia $130,065 2 payments
A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis $107,459 3 payments
PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) $40,793 1 payment
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study To Evaluate The Efficacy and Safety Of CC-90001 In Subjects With Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis $25,211 1 payment
A Phase 3, Multicenter, Open-Label Extension Trial $21,786 1 payment
(RPC01-3101) PhIII RPC1063 Induction and Maintenance in Moderate to Severe UC TRUENORTH (BMS Study Number: IM047-P22) $17,890 1 payment
PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) - A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis $10,540 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.